Loading...
BAX logo
BAX
Baxter International

Aging Populations And Rising Chronic Disease Will Expand Care Access

Published
14 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$43.95
50.0% undervalued intrinsic discount
10 Sep
US$21.98
Loading
1Y
-43.5%
7D
-4.5%

Author's Valuation

US$43.95

50.0% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 17%

Read more

Shared on30 Apr 25
Fair value Increased 0.057%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 14%

AnalystHighTarget has increased future PE multiple from 30.4x to 34.7x.

Read more

Shared on16 Apr 25
Fair value Decreased 11%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more